The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, 400000, China
NCT Number: NCT05635279
Primary liver cancer has recently ranked among the leading causes of cancer death, with hepatocellular carcinoma (HCC) accounting for 75%-85% of these cases. In recent years, immune checkpoint inhibitors (ICIs) combined with tyrosine kinase inhibitors (TKIs) have achieved good results in the treatment of advanced HCC patients. So far, there is a lack of studies exploring the relationship between nutritional index and the prognosis of HCC patients treated with ICIs combined with TKIs, and there are few studies on the prognostic value of nutritional index in HCC patients treated with transarterial chemoembolization (TACE). This retrospective study aims to analyze the prognostic value of prognostic nutritional index(PNI),body mass index (BMI), psoas muscle index(PMI)and geriatric nutritional risk index (GNRI) in HCC patients who received ICIs combined with TKIs or TACE, and to provide reference for the selection of nutritional intervention programs for HCC patients.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Observational
Chongqing, Chongqing Municipality, 400000, China
Patients who confirmed HCC in the Second Affiliated Hospital of Chongqing Medical University were enrolled in the retrospective study. The subjects were divided into two cohorts, both of which met the inclusion and exclusion criteria.The data needed to be collected included age, gender, height and weight at initial treatment and regular follow-up. Blood routine, liver function, kidney function, coagulation function, electrolytes, PIVKA-II, AFP, HBV-DNA, CT, MRI information, China liver cancer staging (CNLC), complications, treatment plan, etc. Follow-up time after initiation of treatment and time of death or significant disease progression. The survival was estimated by the Kaplan-Meier method and curves were compared by the log-rank test.Logistic regression was used to univariate and multivariate analyze the effect of variables on the outcome. Variables with P<0.05 on a univariate analysis were subjected to a multivariate analysis.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Cohort 1:HCC patients received ICIs combined with TKIs regularly and periodically.
Cohort 2:HCC patients who underwent TACE as initial treatment.
Exclusion criteria
Time frame: November 2022 to May 2024
Death due to hepatocellular carcinoma progression
Time frame: November 2022 to May 2024
Death due to other causes such as car accidents or loss to follow-up
Juan Kang
Other
Study on the Effect of Nutritional Indices on the Prognosis of Hepatocellular Carcinoma Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04892810
Adenocarcinoma, Carcinoma
Grenoble, France
View Trial DetailsNCT04930315
Adenocarcinoma, Carcinoma
Hangzhou, Zhejiang, China
View Trial DetailsNCT05128032
Adenocarcinoma, Carcinoma
Boston, Massachusetts, United States
View Trial DetailsNCT04374877
Adenocarcinoma, Advanced Solid Tumor
Duarte, California, United States
View Trial Details